Neogen Corporation Amends Incentive Plan Following Approval
Neogen Corporation's shareholders approve an amended incentive plan, allowing for a wider range of equity-based awards to boost employee engagement.
Oruka Therapeutics reports positive Phase 2b trial results
Oruka Therapeutics announces encouraging results from its Phase 2b trial of ORKA-001 for psoriasis, paving the way for Phase 3 trials in 2027.
Phathom Pharmaceuticals Responds to FDA Docket on VOQUEZNA
Phathom Pharmaceuticals reacts to FDA's public docket on VOQUEZNA's exclusivity, amid ongoing litigation with BDR Pharmaceuticals.
Eikon Therapeutics presents clinical data at oncology congress
Eikon Therapeutics shares promising clinical data from its PARP1 and WRN helicase programs at the European Society for Medical Oncology Congress.
Federal Home Loan Bank of Boston Elects Four New Directors
Federal Home Loan Bank of Boston announces election of four new directors effective January 1, 2027, alongside updated compensation policies.